

M. Sakanaka, et al.  
U.S.S.N. 09/913,669  
Page 2

**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims:**

1-31. (Cancelled).

32. (New) A method for the treatment of diseases caused by injuries to nervous tissues or to the spinal cord, the method comprising the step of administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising a therapeutic agent selected from ginsenoside Rb<sub>1</sub>, its metabolites and salts thereof.

33. (New) The method of claim 32, wherein the pharmaceutical composition is capable of suppressing the secondary degeneration of the nervous tissues caused by injuries to the nervous tissues or to the spinal cord.

34. (New) The method of claim 33, wherein the secondary degeneration of the nervous tissues is caused by a spinal cord injury.

35. (New) The method of claim 32, wherein the therapeutic agent is capable of ameliorating paralysis or paraplegia.

36. (New) The method of claim 35, wherein the paralysis or paraplegia is caused by a spinal cord injury.

37. (New) The method of claim 32 wherein the secondary degeneration of the nervous tissues is caused by a traumatic injury.

M. Sakanaka, et al.  
U.S.S.N. 09/913,669  
Page 3

38. (New) The method of claim 32, wherein the pharmaceutical composition is capable of suppressing the secondary degeneration of the nervous tissues caused by demyelination.

39. (New) The method of claim 38, wherein the pharmaceutical composition is capable of suppressing apoptosis or apoptosis-like cell death of oligodendrocytes.

40. (New) The method of claim 32, wherein the pharmaceutical composition is administered intravenously to the patient.

41. (New) The method of claim 32, wherein the pharmaceutical composition is administered in a single intravenous infusion or in a continuous intravenous infusion to the patient.

42. (New) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition provides a concentration of ginsenoside Rb<sub>1</sub>, its metabolites or salts thereof to the extracellular fluid in lesion at a concentration of 1 ng/ml or less.

43. (New) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition provides a concentration of ginsenoside Rb<sub>1</sub>, its metabolites or salts thereof to the extracellular fluid in lesion at a concentration of 1 pg/ml or less.

44. (New) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition provides a concentration of ginsenoside Rb<sub>1</sub>, its metabolites or salts thereof to the extracellular fluid in lesion at a concentration of 100 fg/ml or less.

M. Sakanaka, et al.  
U.S.S.N. 09/913,669  
Page 4

45. (New) A method for promoting vascular regeneration and or reconstruction, the method comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising a therapeutic agent selected from ginsenoside Rb<sub>1</sub>, its metabolites and salts thereof.

46. (New) A method for treating trauma or traumatic injuries, the method comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising a therapeutic agent selected from ginsenoside Rb<sub>1</sub>, its metabolites and salts thereof.

47. (New) The method of claim 46, wherein the trauma or traumatic injuries are caused by spinal cord injuries, neurotrauma, or head injuries.

48. (New) A method for suppressing apoptosis or apoptosis-like cell death of oligodendrocytes, the method comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising a therapeutic agent selected from ginsenoside Rb<sub>1</sub>, its metabolites and salts thereof.

49. (New) The method of claim 48, wherein the apoptosis or apoptosis-like cell death of the oligodendrocytes is caused by spinal cord injuries.

50. (New) A method for treatment of injuries caused by demyelination, the method comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising a therapeutic agent selected from ginsenoside Rb<sub>1</sub>, its metabolites and salts thereof.

51. (New) The method of claim 50, wherein the demyelination is caused by a spinal cord injury.